Current Status and Challenges of CAR-T Immunotherapy in Hematologic Malignancies -Review / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 626-630, 2018.
Article
em Zh
| WPRIM
| ID: wpr-690938
Biblioteca responsável:
WPRO
ABSTRACT
The chimeric antigen receptor (CAR) T cell therapy has gradually became a new trend in the treatment of refractory and relapsed hematologic malignancies by developing for 30 years. With the exciting development of genetic engineering, CAR-T technology has subjected to 4 generations of innovation. Structure of CAR-T started from a single signal molecule to 2 or more than 2 co-stimulatory molecules, and then coding the CAR gene or promoter. CAR-T can specifically recognize tumor antigens, and does not be restricted by major histocompatibility complex (MHC), thus making a breakthrough in clinical treatment. In this review, the history, structure and mechanism of action of CAR-T, as well as the current status and challenges of CAR-T immunotherapy in acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia and multiple myeloma are summarized.
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Terapêutica
/
Receptores de Antígenos de Linfócitos T
/
Linfócitos T
/
Imunoterapia Adotiva
/
Antígenos CD19
/
Neoplasias Hematológicas
/
Imunoterapia
Limite:
Humans
Idioma:
Zh
Revista:
Journal of Experimental Hematology
Ano de publicação:
2018
Tipo de documento:
Article